News blog

Instem

  • BY: Andrew Hore |
  • POSTED: 10/01/2013 |

Instem managed to sign the contracts it needed to in order to meet 2012 expectations. 

Licence income is second-half weighted and many contracts are signed near to the end of the year.

Last year, N+1 Singer downgraded its 2012 profit expectations from £2.2m to £1.1m – based on flat revenues of £10.8m – although that was long before December’s trading statement.

JOINN Laboratories, which is China’s largest provider of preclinical studies, has purchased Instem’s Provantis preclinical software.

At 89.5p a share, Instem is valued at £10.5m. There was £2.2m in the bank at the end of 2012. There will be a cash inflow in the first quarter

The 2012 figures will be released on 27 March.

Download the latest AIM Journal from http://www.hubinvest.com/AIMPDFDecember2012_39.pdf

© 2024 Aim Micro. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Browse by issue
All issues
Popular tags
All tags

betbrokers, financial, gold, health, leisure, media, mobile, resources, services, technology

AIM Micro feeds

Keep up to date with articles published at AIMMicro.com. Subscribe to AIM Micro RSS Feeds